On the other hand, children and adolescents are frequently treated using medicines without proven efficacy and, in particular, without proven tolerability..
This is not at all the case for EPs® 7630: In various studies, including one from 2012*, scientists have confirmed that EPs® helps patients to recover more quickly while being safe and well tolerated.
The recent investigation included 200 children and adolescents between 1 and 18 years of age who had acute bronchitis including typical complaints such as cough and difficulties in breathing. Half of the participants were given placebos whereas the other half received the active substance EPs® 7630. The result of this trial: Patients in the EPs® group showed a significantly faster improvement of the symptoms. After seven days of treatment with EPs®, nearly 60% of the children could return to kindergarten or school, whereas this was the case for only 17% within the placebo group. This study demonstrates again the clinically proven efficacy and safety of EPs® — particularly in children and adolescents.
*Kamin et al, Pediatrics International 2012; 54; 219 – 226